docetaxel anhydrous has been researched along with zearalenone in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (zearalenone) | Trials (zearalenone) | Recent Studies (post-2010) (zearalenone) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 2,356 | 41 | 1,352 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | zearalenone (IC50) |
|---|---|---|---|
| 90-kda heat shock protein beta HSP90 beta, partial | Homo sapiens (human) | 2.402 | |
| PTK2B protein tyrosine kinase 2 beta | Homo sapiens (human) | 6.922 | |
| heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | 2.402 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bencivenga, M; Carbone, C; De Manzoni, G; Frizziero, M; Giacopuzzi, S; Melisi, D; Merz, V; Mina, MM; Piro, G; Santoro, R; Tortora, G; Verlato, G; Zanoni, A; Zanotto, M | 1 |
1 other study(ies) available for docetaxel anhydrous and zearalenone
| Article | Year |
|---|---|
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; In Vitro Techniques; Inhibitor of Apoptosis Proteins; Male; MAP Kinase Kinase Kinases; Middle Aged; Neoplasm Proteins; Radiation Tolerance; RNA, Messenger; ROC Curve; Taxoids; Ubiquitin-Protein Ligases; Zearalenone | 2015 |